Company: CPMV
Filing Date: 2025-08-19
Form Type: 10-Q
Source: 0001683168-25-006318
Chunk: 4

Company: Mosaic ImmunoEngineering Inc.
Filing Date: 2025-08-19
Form: 10-Q
Item: Part I, Item 1
Chunk 4
---
     (353,348)

    Balances, June 30, 2025 
    – 
    $–  
    70,000 
    $1  
    7,242,137 
    $72  
    $2,050,073  
    $(9,191,668) 
    $(7,141,522)

For the Six Months Ended June 30, 2024

    Series A
    Convertible Voting Preferred Stock 
    Series B
    Convertible Voting Preferred Stock 
    Common
    Stock  
    Additional
    Paid-in  
    Accumulated  
    Total Stockholders' 

    Shares  
    Amount 
    Shares  
    Amount 
    Shares  
    Amount  
    Capital  
    Deficit  
    Deficit 
  
    Balances, January 1, 2024 
    –  
    $– 
    70,000  
    $1 
    7,242,137  
    $72  
    $2,045,206  
    $(7,916,337) 
    $(5,871,058)

    Share-based compensation 
    –  
     – 
    –  
     – 
    –  
     –  
     4,867  
     –  
     4,867 

    Net loss 
    –  
     – 
    –  
     – 
    –  
     –  
     –  
     (582,209) 
     (582,209)

    Balances, June 30, 2024 
    –  
    $– 
    70,000  
    $1 
    7,242,137  
    $72  
    $2,050,073  
    $(8,498,546) 
    $(6,448,400)

See accompanying notes to unaudited condensed consolidated
financial statements.

 6 

Mosaic ImmunoEngineering, Inc.

Condensed Consolidated Statement of Cash Flows

(Unaudited)

    For the Six Months Ended June 30, 

    2025  
    2024 
  
    Operating activities: 

    Net loss 
    $(353,348) 
    $(582,209)
  
    Adjustments to reconcile net loss to net cash